Clinical Trial Update: Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating MK2206 (Akt inhibitor) or everolimus in refractory kidney cancer; study terminated with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Everolimus (everolimus)
• MK2206 (MK2206)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Kidney Carcinoma, Recurrent Renal Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2017-06-07